Dashboard Market News Pricing Contact Us
Search 100,000+ stocks...
English EN
Deutsch DE Español ES
Sign Up
Log in
Lotus Pharmaceutical Co Ltd banner

Lotus Pharmaceutical Co Ltd
TWSE:1795

Watchlist Manager
Lotus Pharmaceutical Co Ltd Logo
Lotus Pharmaceutical Co Ltd
TWSE:1795
Watchlist
Price: 180 TWD
Market Cap: NT$48B
Write Note Create Alert Ask AI

Wall St Price Targets

Price Targets Summary
Lotus Pharmaceutical Co Ltd

Wall Street analysts forecast Lotus Pharmaceutical Co Ltd stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for Lotus Pharmaceutical Co Ltd is 394.71 TWD with a low forecast of 219.35 TWD and a high forecast of 518.26 TWD.

Lowest Forecast
Wall Street Target
NT$219.35
22% Upside
Average Forecast
Wall Street Target
NT$394.71
119% Upside
Highest Forecast
Wall Street Target
NT$518.26
188% Upside
Lowest Forecast
Price Target
219.35 TWD
22% Upside
Average Forecast
Price Target
394.71 TWD
119% Upside
Highest Forecast
Price Target
518.26 TWD
188% Upside
Lotus Pharmaceutical Co Ltd Competitors:
Price Targets

Revenue
Forecast

33% / Year
Past Growth
44% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss
33% / Year
Past Growth
44% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss

Over the last 13 years, the compound annual growth rate for Revenue has been 33%. The projected CAGR for the next 2 years is 44%.

What are analyst estimates?

Gross Profit
Forecast

34% / Year
Past Growth
41% / Year
Estimated Growth
Estimates Accuracy
-2%
Average Miss
34% / Year
Past Growth
41% / Year
Estimated Growth
Estimates Accuracy
-2%
Average Miss

Over the last 13 years, the compound annual growth rate for Gross Profit has been 34%. The projected CAGR for the next 2 years is 41%.

What are analyst estimates?

Operating Income
Forecast

N/A
Past Growth
42% / Year
Estimated Growth
Estimates Accuracy
-7%
Average Miss
N/A
Past Growth
42% / Year
Estimated Growth
Estimates Accuracy
-7%
Average Miss

The compound annual growth rate for Operating Income over the next 2 years is 42%.

What are analyst estimates?

Pre-Tax Income
Forecast

N/A
Past Growth
22% / Year
Estimated Growth
Estimates Accuracy
-5%
Average Miss
N/A
Past Growth
22% / Year
Estimated Growth
Estimates Accuracy
-5%
Average Miss

The compound annual growth rate for Pre-Tax Income over the next 2 years is 22%.

What are analyst estimates?

Net Income
Forecast

N/A
Past Growth
19% / Year
Estimated Growth
Estimates Accuracy
-3%
Average Miss
N/A
Past Growth
19% / Year
Estimated Growth
Estimates Accuracy
-3%
Average Miss

The compound annual growth rate for Net Income over the next 2 years is 19%.

What are analyst estimates?

Continue Research

Summary
intrinsic value, competitors valuation, and company profile.
DCF Valuation
stock valuation using Discount Cash Flow valuation method.
Relative Valuation
stock valuation using valuation multiples.
Wall St Estimates
price targets and financial estimates made by Wall Street analysts.
Profitability
Detailed analysis of the company's profitability.
Solvency
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall St Estimates
Profitability
Solvency
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is Lotus Pharmaceutical Co Ltd's stock price target?
Price Target
394.71 TWD

According to Wall Street analysts, the average 1-year price target for Lotus Pharmaceutical Co Ltd is 394.71 TWD with a low forecast of 219.35 TWD and a high forecast of 518.26 TWD.

What is the Revenue forecast for Lotus Pharmaceutical Co Ltd?
Projected CAGR
44%

Over the last 13 years, the compound annual growth rate for Revenue has been 33%. The projected CAGR for the next 2 years is 44%.

What is the Gross Profit forecast for Lotus Pharmaceutical Co Ltd?
Projected CAGR
41%

Over the last 13 years, the compound annual growth rate for Gross Profit has been 34%. The projected CAGR for the next 2 years is 41%.

What is the Operating Income forecast for Lotus Pharmaceutical Co Ltd?
Projected CAGR
42%

The compound annual growth rate for Operating Income over the next 2 years is 42%.

What is the Pre-Tax Income forecast for Lotus Pharmaceutical Co Ltd?
Projected CAGR
22%

The compound annual growth rate for Pre-Tax Income over the next 2 years is 22%.

What is the Net Income forecast for Lotus Pharmaceutical Co Ltd?
Projected CAGR
19%

The compound annual growth rate for Net Income over the next 2 years is 19%.

Back to Top
ALPHA SPREAD
Follow us
Join 358,200+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Valuation Backtest Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.